Expert opinion: Professor Gregory Mattingly on REXULTI® (brexpiprazole) and treating schizophrenia
Professor Gregory Mattingly provides his expert opinion on optimising the management of patients with schizophrenia, including the role of REXULTI®.
-
BoxBody
REXULTI PBS Information: Authority required (STREAMLINED). Code: 4246 for schizophrenia
-
textBody
Please review Approved Product Information before prescribing.
Product Information is available by calling Lundbeck on 1300 721 277 or by clicking:REXULTI® is a registered trademark of H. Lundbeck A/S. REXULTI® is co-commercialised by Lundbeck Australia and Otsuka Australia Pharmaceutical Pty Limited.
Contributor
Dr Gregory Mattingly